April 28th, 2015
No Advantage to Adding Inferior Vena Cava Filters to Anticoagulation
Larry Husten, PHD
Despite a lack of supporting evidence many patients with acute venous thromboembolism (VTE) receive inferior vena cava filters to prevent pulmonary embolism (PE). Now a new study published in JAMA offers no evidence of benefit for the use of these devices in a high-risk population already receiving anticoagulant drugs. A group of French physicians randomized nearly 400 […]
January 12th, 2015
Selections from Richard Lehman’s Literature Review: January 12th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include the effects of BP reduction in mild hypertension, the association between dietary whole grain intake and risk of mortality, and more.
December 8th, 2014
New Anticoagulant Spotlights Major Role for the Intrinsic Pathway
Sanjay Kaul, MD and Ethan J Weiss, M.D.
Sanjay Kaul and Ethan Weiss discuss an entirely new approach to anticoagulation.
December 1st, 2014
Selections from Richard Lehman’s Literature Review: December 1st
Richard Lehman, BM, BCh, MRCGP
This week’s topics include atenolol vs. losartan in children and young adults with Marfan’s syndrome, the Japanese Primary Prevention Project, and more.
June 23rd, 2014
FDA: Risk for Venous Thromboembolism with All Testosterone Products
Kristin J. Kelley, CardioExchange Staff
The FDA is requiring an expanded label change to all approved testosterone products to warn of the increased risk for venous thromboembolism. Labels currently address the risk for clots associated with polycythemia caused by testosterone treatment. The action follows reports of blood clots in testosterone users unrelated to polycythemia. The agency says the warning is not […]
March 6th, 2014
Vena Cava Filters Reduce Pulmonary Emboli But Increase VTE Recurrence Tenfold
Inferior vena cava filters seem to offer protection against death from pulmonary embolism when compared with anticoagulant therapy, but they have no significant effect on all-cause mortality. In addition, the filters are associated with higher rates of recurrent venous thromboembolism, according to an article in the Journal of the American College of Cardiology. Researchers examined data […]
December 18th, 2013
New Trial Confirms Role for Dabigatran in Venous Thromboembolism
Larry Husten, PHD
A new study helps support a role for the new oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim) in patients with venous thrombosis (VTE). The RE-COVER II trial, published online in Circulation, confirms the finding of the earlier and highly similar RE-COVER trial, published in the New England Journal of Medicine in 2009, that dabigatran is as safe and effective as warfarin for […]
December 2nd, 2013
Selections from Richard Lehman’s Literature Review: December 2nd
Richard Lehman, BM, BCh, MRCGP
This week’s topic is the risk for first VTE among pregnant women who are hospitalized.
October 14th, 2013
Selections from Richard Lehman’s Literature Review: October 14th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include CRT in HF with a narrow QRS complex, a trial of edoxaban vs. warfarin for symptomatic VTE, and more.
September 18th, 2013
Is Edoxaban the Most Promising of the Novel Anticoagulants?
Samuel Goldhaber, MD
Samuel Z. Goldhaber offers his perspective on the Hokusai-VTE randomized trial comparing edoxaban and warfarin in patients with symptomatic venous thromboembolism.
NEJM Journal Watch — Recent Cardiology Articles- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?
- Are Angiographically-Derived Coronary Physiology Measurements Ready for Use in the Cath Lab?